Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease

Amy L. Lightner, V Loftus Edward V Loftus, Nicholas P. McKenna, Laura E. Raffals

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: The isolated effect of vedolizumab on increased postoperative complications remains debated, similar to the controversial data on anti-TNF and postoperative complications. OBJECTIVE: To determine the risk of vedolizumab on postoperative complications. METHODS: A review of the literature available to date on studies comparing postoperative outcomes in vedolizumab-treated versus non-vedolizumab-treated patients was performed. Studies were stratified by those which combined all inflammatory bowel disease together, those specifically focusing on Crohn's disease or ulcerative colitis individually, and those which included pediatric patients alone. RESULTS: The data remains controversial in both the adult and pediatric literature regarding the association of vedolizumab and increased postoperative complications. The strongest association between vedolizumab and an increased risk of postoperative infectious complications seems to be in the Crohn's disease literature. CONCLUSION: Vedolizumab may be associated with an increased risk of postoperative infectious complications in Crohn's disease, but the literature remains controversial due to difficulty in isolating the effect of the biologic alone in a chronically ill, heterogeneous patient population who are on multiple medications including corticosteroids.

Original languageEnglish (US)
Pages (from-to)1317-1322
Number of pages6
JournalCurrent drug targets
Volume20
Issue number13
DOIs
StatePublished - Jan 1 2019

Fingerprint

Inflammatory Bowel Diseases
Crohn Disease
Pediatrics
Ulcerative Colitis
vedolizumab
Adrenal Cortex Hormones
Chronic Disease
Population

Keywords

  • Crohn’s disease
  • inflammatory bowel disease
  • intraabdominal sepsis
  • postoperative infectious complications
  • surgical intervention
  • ulcerative colitis.
  • Vedolizumab

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease. / Lightner, Amy L.; Edward V Loftus, V Loftus; McKenna, Nicholas P.; Raffals, Laura E.

In: Current drug targets, Vol. 20, No. 13, 01.01.2019, p. 1317-1322.

Research output: Contribution to journalArticle

Lightner, Amy L. ; Edward V Loftus, V Loftus ; McKenna, Nicholas P. ; Raffals, Laura E. / Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease. In: Current drug targets. 2019 ; Vol. 20, No. 13. pp. 1317-1322.
@article{d3309f308aa046af813e5fcfd218efcf,
title = "Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease",
abstract = "BACKGROUND: The isolated effect of vedolizumab on increased postoperative complications remains debated, similar to the controversial data on anti-TNF and postoperative complications. OBJECTIVE: To determine the risk of vedolizumab on postoperative complications. METHODS: A review of the literature available to date on studies comparing postoperative outcomes in vedolizumab-treated versus non-vedolizumab-treated patients was performed. Studies were stratified by those which combined all inflammatory bowel disease together, those specifically focusing on Crohn's disease or ulcerative colitis individually, and those which included pediatric patients alone. RESULTS: The data remains controversial in both the adult and pediatric literature regarding the association of vedolizumab and increased postoperative complications. The strongest association between vedolizumab and an increased risk of postoperative infectious complications seems to be in the Crohn's disease literature. CONCLUSION: Vedolizumab may be associated with an increased risk of postoperative infectious complications in Crohn's disease, but the literature remains controversial due to difficulty in isolating the effect of the biologic alone in a chronically ill, heterogeneous patient population who are on multiple medications including corticosteroids.",
keywords = "Crohn’s disease, inflammatory bowel disease, intraabdominal sepsis, postoperative infectious complications, surgical intervention, ulcerative colitis., Vedolizumab",
author = "Lightner, {Amy L.} and {Edward V Loftus}, {V Loftus} and McKenna, {Nicholas P.} and Raffals, {Laura E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1389450120666190325130142",
language = "English (US)",
volume = "20",
pages = "1317--1322",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Vedolizumab in the Perioperative Management of Inflammatory Bowel Disease

AU - Lightner, Amy L.

AU - Edward V Loftus, V Loftus

AU - McKenna, Nicholas P.

AU - Raffals, Laura E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - BACKGROUND: The isolated effect of vedolizumab on increased postoperative complications remains debated, similar to the controversial data on anti-TNF and postoperative complications. OBJECTIVE: To determine the risk of vedolizumab on postoperative complications. METHODS: A review of the literature available to date on studies comparing postoperative outcomes in vedolizumab-treated versus non-vedolizumab-treated patients was performed. Studies were stratified by those which combined all inflammatory bowel disease together, those specifically focusing on Crohn's disease or ulcerative colitis individually, and those which included pediatric patients alone. RESULTS: The data remains controversial in both the adult and pediatric literature regarding the association of vedolizumab and increased postoperative complications. The strongest association between vedolizumab and an increased risk of postoperative infectious complications seems to be in the Crohn's disease literature. CONCLUSION: Vedolizumab may be associated with an increased risk of postoperative infectious complications in Crohn's disease, but the literature remains controversial due to difficulty in isolating the effect of the biologic alone in a chronically ill, heterogeneous patient population who are on multiple medications including corticosteroids.

AB - BACKGROUND: The isolated effect of vedolizumab on increased postoperative complications remains debated, similar to the controversial data on anti-TNF and postoperative complications. OBJECTIVE: To determine the risk of vedolizumab on postoperative complications. METHODS: A review of the literature available to date on studies comparing postoperative outcomes in vedolizumab-treated versus non-vedolizumab-treated patients was performed. Studies were stratified by those which combined all inflammatory bowel disease together, those specifically focusing on Crohn's disease or ulcerative colitis individually, and those which included pediatric patients alone. RESULTS: The data remains controversial in both the adult and pediatric literature regarding the association of vedolizumab and increased postoperative complications. The strongest association between vedolizumab and an increased risk of postoperative infectious complications seems to be in the Crohn's disease literature. CONCLUSION: Vedolizumab may be associated with an increased risk of postoperative infectious complications in Crohn's disease, but the literature remains controversial due to difficulty in isolating the effect of the biologic alone in a chronically ill, heterogeneous patient population who are on multiple medications including corticosteroids.

KW - Crohn’s disease

KW - inflammatory bowel disease

KW - intraabdominal sepsis

KW - postoperative infectious complications

KW - surgical intervention

KW - ulcerative colitis.

KW - Vedolizumab

UR - http://www.scopus.com/inward/record.url?scp=85072687239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072687239&partnerID=8YFLogxK

U2 - 10.2174/1389450120666190325130142

DO - 10.2174/1389450120666190325130142

M3 - Article

C2 - 30914021

AN - SCOPUS:85072687239

VL - 20

SP - 1317

EP - 1322

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 13

ER -